Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprex in metastatic breast cancer anemia
NCT00211133Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2000
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
A Phase 3 trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Started Jun 2000; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00211133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211133.